Abstract
This systematic review evaluates the prevalence of long-term complications of serogroup B meningococcal disease (MD) in light of the recent licensure of a vaccine against meningococcal B disease. Twelve appropriate studies were identified by searching available databases from 1946 to July 2014. The average prevalence of hearing impairment was 4.2% among serogroup B MD survivors; 2.3% suffered amputation and 2.3% developed seizures. When compared with complications due to non-meningococcal B bacterial meningitis, physical impairment and seizures were more common in survivors of meningococcal B disease but hearing impairment had similar prevalence. Few studies quantified less frequent complications such as visual impairment and cognitive dysfunction. Better comprehensive reporting of the complications and costs of serogroup B MD in survivors and their families is needed to inform vaccination policy.
Keywords: Complications, meningococcal disease, serogroup B.
Infectious Disorders - Drug Targets
Title:Complications of Serogroup B Meningococcal Disease in Survivors: A Review
Volume: 14 Issue: 3
Author(s): Fereshteh Dastouri, Ahmad Mirmohammad Hosseini, Elizabeth Haworth, Gulam Khandaker, Harunor Rashid and Robert Booy
Affiliation:
Keywords: Complications, meningococcal disease, serogroup B.
Abstract: This systematic review evaluates the prevalence of long-term complications of serogroup B meningococcal disease (MD) in light of the recent licensure of a vaccine against meningococcal B disease. Twelve appropriate studies were identified by searching available databases from 1946 to July 2014. The average prevalence of hearing impairment was 4.2% among serogroup B MD survivors; 2.3% suffered amputation and 2.3% developed seizures. When compared with complications due to non-meningococcal B bacterial meningitis, physical impairment and seizures were more common in survivors of meningococcal B disease but hearing impairment had similar prevalence. Few studies quantified less frequent complications such as visual impairment and cognitive dysfunction. Better comprehensive reporting of the complications and costs of serogroup B MD in survivors and their families is needed to inform vaccination policy.
Export Options
About this article
Cite this article as:
Dastouri Fereshteh, Mirmohammad Hosseini Ahmad, Haworth Elizabeth, Khandaker Gulam, Rashid Harunor and Booy Robert, Complications of Serogroup B Meningococcal Disease in Survivors: A Review, Infectious Disorders - Drug Targets 2014; 14 (3) . https://dx.doi.org/10.2174/1871526515999150320155614
DOI https://dx.doi.org/10.2174/1871526515999150320155614 |
Print ISSN 1871-5265 |
Publisher Name Bentham Science Publisher |
Online ISSN 2212-3989 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Efficient Synthesis and Antibacterial Profile of Bis(2-hydroxynaphthalene- 1,4-dione)
Current Topics in Medicinal Chemistry Pathogenesis of Central Nervous System Tuberculosis
Current Molecular Medicine New Progress in Azole Compounds as Antimicrobial Agents
Mini-Reviews in Medicinal Chemistry Adenosine and the Auditory System
Current Neuropharmacology Dendritic Cells and Macrophages: Same Receptors but Different Functions
Current Immunology Reviews (Discontinued) Serratia Type Pore Forming Toxins
Current Protein & Peptide Science Brucellosis Serostatus Among Pregnant Women with Spontaneous Abortion and Stillbirth
Current Women`s Health Reviews Perspectives and New Aspects of Metalloproteinases’ Inhibitors in the Therapy of CNS Disorders: From Chemistry to Medicine
Current Medicinal Chemistry Topological Model for the Search of New Antibacterial Drugs. 158 Theoretical Candidates
Current Computer-Aided Drug Design Is there a Rational Approach for Increasing Drug Specificity? Considerations on CNS Target Choice and Validation
Recent Patents on CNS Drug Discovery (Discontinued) The Blood Brain Barrier, Mechanisms of Cerebral Edema, and the Use of Anti-Inflammatory and other Anti-Edema Agents in Neuro-Oncology
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Novel Antibacterial Agents: An Emergent Need to Win the Battle Against Infections
Mini-Reviews in Medicinal Chemistry Bacterial Protein Microarrays for Diagnosis of Infectious Diseases
Current Immunology Reviews (Discontinued) The Association of Collagenase with Human Diseases and its Therapeutic Potential in Overcoming them
Current Biotechnology Kynurenine Pathway and Disease: An Overview
CNS & Neurological Disorders - Drug Targets Development of Reverse Phase Ultra-fast Liquid Chromatography Using Ion-pairing Reagent for Quantitative Assessment of Ceftriaxone in Rat Serum and Cerebrospinal Fluid
Current Pharmaceutical Analysis Withdrawal Notice: Neuroprotective Effect of Lithospermum officinale callus Extract on Inflamed Primary Microglial Cells
Current Pharmaceutical Biotechnology Closed-loop Neuropharmacology for Epilepsy: Distant Dream or Future Reality?
Current Neuropharmacology Cytochrome P450 Regulation and Drug Biotransformation During Inflammation and Infection
Current Drug Metabolism Central Nervous System Involvement in Pediatric Rheumatic Diseases: Current Concepts in Treatment
Current Pharmaceutical Design